|Table of Contents|

Clinical value of double paraffin blocks for the detection of HER-2 in colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1074-1078
Research Field:
Publishing date:

Info

Title:
Clinical value of double paraffin blocks for the detection of HER-2 in colorectal cancer
Author(s):
ZHANG Yongsheng; ZHANG Liping; HAN Jie; GAO Ping; ZHU Xiaoling
Department of Pathology,Rizhao Central Hospital,Shandong Rizhao 276800,China.
Keywords:
colorectal cancer; double paraffin blocks; immunohistochemistry; HER-2; heterogeneity
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2023.06.017
Abstract:
Objective：To study the clinical value of double paraffin blocks for the detection of HER-2 in colorectal cancer,and to analyze the correlation between HER-2 expression and clinicopathological features.Methods:The expression of HER-2 in 228 cases of colorectal cancer was detected by automatic immunohistochemical staining machine.The tumor tissues of two different paraffin blocks were adhered with the same slide.The expression of the paraffin block with the smaller pathological number was the result of the first group,and the joint expression of the two paraffin blocks was the result of the second group.The corresponding clinicopathological features of the two groups were comprehensively analyzed.Results：The percentage of HER-2 score with (0/1+) was 89.5% (204/228) in the first group and 82.5% (188/228) in the second group.The percentage of HER-2 score with (2+/3+) was 10.5% (24/228) in the first group and 17.5% (40/228) in the second group.The detection rate of HER-2 (2+/3+) by double paraffin blocks was significantly higher than that of single paraffin block.The difference between the two groups was statistically significant (χ2=4.653,P=0.031).The expression of HER-2 in colorectal cancer was correlated with the degree of tumor differentiation,depth of invasion and lymph node metastasis (P＜0.05).However,HER-2 expression was not correlated with gender,age,tumor diameter and tumor location (P＞0.05).Conclusion：Immunohistochemistry using double paraffin blocks can improve the detection rate of HER-2 (2+/3+) expression,which will increase the possibility of patients to benefit from anti-HER-2 targeted drug therapy.Over-expression of HER-2 is closely related to the degree of tumor differentiation,depth of invasion and lymph node metastasis.It is suggested that it may be involved in the progression and metastasis of colorectal cancer and help to judge the prognosis.

References:

［1］NGUYEN M,SMITH ST,LAM M,et al.An update on the use of immunotherapy in patients with colorectal cancer［J］.Expert Rev Gastroenterol Hepatol,2021,15(3):291-304.
［2］BENSON AB,VENOOK AP,AL-HAWARY MM,et al.Colon cancer,version 2.2021,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2021,19(3):329-359.
［3］CUYPER AD,EYNDE MVD,MACHIELS JP,et al.HER2 as a predictive biomarker and treatment target in colorectal cancer［J］.Clin Colorectal Cancer,2020,19(2):65-72.
［4］ 陈坚贤.乳腺癌瘤内异质性的研究进展［J］.现代肿瘤医学,2020,28(20):3627-3631. CHEN JX.Research advances on intratumoral heterogeneity of breast cancer［J］.Modern Oncology,2020,28(20):3627-3631.
［5］HALSKE C.Intratumoral heterogeneity of gastric cancer-impact on biomarker evaluation［J］.Pathologe,2020,41(Suppl 2):76-82.
［6］ KILICARSLAN A,DOGAN HT,SVNGV N,et al.Association between Her2/neu status in colorectal carcinoma and clinicopathological features:a retrospective study using whole-tissue sections［J］.Pol J Pathol,2018,69(2):143-149.
［7］ VALTORTA E,MARTINO C,SARTORE-BIANCHI A,et al.Assessment of a HER2 scoring system for colorectal cancer:results from a validation study［J］.Mod Pathol,2015,28(11):1481-1491.
［8］SARTORE-BIANCHI A,TRUSOLINO L,MARTINO C,et al.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory,KRAS codon 12/13 wild-type,HER2-positive metastatic colorectal cancer (HERACLES):a proof-of-concept,multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2016,17(6):738-746.
［9］ MERIC-BERNSTAM F,HURWITZ H,RAGHAV KPS,et al.Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study［J］.Lancet Oncol,2019,20(4):518-530.
［10］GUARINI C,GRASSI T,PEZZICOLI G,et al.Beyond RAS and BRAF:HER2,a new actionable oncotarget in advanced colorectal cancer［J］.Int J Mol Sci,2021,22(13):6813.
［11］ WOLFF AC,HAMMOND MEH,ALLISON KH,et al.Human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update［J］.J Clin Oncol,2018,36(20):2105-2122.
［12］ BARTLEY AN,WASHINGTON MK,VENTURA CB,et al.HER2 testing and clinical decision making in gastroesophageal adenocarcinoma:Guideline from the college of American pathologists,American society for clinical pathology,and American society of clinical oncology［J］.Am J Clin Pathol,2016,146(6):647-669.
［13］LIU FR,REN C,JIN Y,et al.Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer［J］.Virchows Arch,2020,476(3):391-398.
［14］ZHAO D,KLEMPNER SJ,CHAO J.Progress and challenges in HER2-positive gastroesophageal adenocarcinoma ［J］.J Hematol Oncol,2019,12(1):50.
［15］曹勇,于大海.肿瘤进化异质性研究现状及进展［J］.现代肿瘤医学,2022,30(2):329-332. CAO Y,YU DH.Research status and progress on tumor evolutionary heterogeneity［J］.Modern Oncology,2022,30(2):329-332.
［16］ZHENG Z,YU T,ZHAO X,et al.Intratumor heterogeneity:A new perspective on colorectal cancer research［J］.Cancer Med,2020,9(20):7637-7645.
［17］FUSCO N,BOSARI S.HER2 aberrations and heterogeneity in cancers of the digestive system:Implications for pathologists and gastroenterologists［J］.World J Gastroenterol,2016,22(35):7926-7937.
［18］ZHANG H,WANG Y,WANG Y,et al.Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer ［J］.Pathol Res Pract,2020,216(11):153229.
［19］陈旭东,吴雅,蔡南南,等.多蜡块HER2在胃癌的应用价值［J］.诊断病理学杂志,2019,26(12):839-843. CHEN XD,WU Y,CAI NN,et al.Clinical application of multiple paraffin blocks for the detection of HER2 status in gastric cancer［J］.Chinese Journal of Diagnostic Pathology,2019,26(12):839-843.
［20］ROSS JS,FAKIH M,ALI SM,et al.Targeting HER2 in colorectal cancer:The landscape of amplification and short variant mutations in ERBB2 and ERBB3［J］.Cancer,2018,124(7):1358-1373.
［21］RICHMAN SD,SOUTHWARD K,CHAMBERS P,et al.HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer:analysis of 3256 patients enrolled in the QUASAR,FOCUS and PICCOLO colorectal cancer trials［J］.J Pathol,2016,238(4):562-570.
［22］SUN SJ,LIN Q,SUN Q,et al.High HER-2 protein levels correlate with clinicopathological features in colorectal cancer［J］.J Can Res Ther,2016,12(1):323-333.
［23］YANG WJ,SHEN XJ,MA XX,et al.Correlation of human epidermal growth factor receptor protein expression and colorectal cancer［J］.World J Gastroenterol,2015,21(28):8687-8696.

Memo

Memo:
-
Last Update: 1900-01-01